Literature DB >> 30364934

Activity of EGFR antibody in non-V600 BRAF mutant metastatic colorectal cancer.

Y Wang1, J C Jones1, B R Kipp2, A Grothey3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30364934     DOI： 10.1093/annonc/mdy477

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

Review 1.  Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer.

Authors:  Benny Johnson; Scott Kopetz
Journal:  Target Oncol       Date:  2020-10       Impact factor: 4.493

2.  Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.

Authors:  Rona Yaeger; Daisuke Kotani; Sebastián Mondaca; Aparna R Parikh; Hideaki Bando; Emily E Van Seventer; Hiroya Taniguchi; HuiYong Zhao; Claire N Thant; Elisa de Stanchina; Neal Rosen; Ryan B Corcoran; Takayuki Yoshino; Zhan Yao; Hiromichi Ebi
Journal:  Clin Cancer Res       Date:  2019-09-12       Impact factor: 12.531

Review 3.  Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies.

Authors:  Christine M Parseghian; Stefania Napolitano; Jonathan M Loree; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2019-07-01       Impact factor: 12.531

Review 4.  Lobaplatin hyperthermic intraperitoneal chemotherapy plus cytoreduction and rechallenge using cetuximab for wild-type RAS peritoneal metastatic colon cancer: a case report and literature review.

Authors:  Peilin Dai; Zaisheng Ye; Zhai Cai; Zeyu Luo; Enming Qiu; Yu Lin; Jian Cai; Hui Wang; Zhou Li; Shuai Han
Journal:  BMC Gastroenterol       Date:  2022-02-14       Impact factor: 3.067
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.